Plasma Fractionation Market by Product (Coagulation Factor Concentrates, Immunoglobulin, Protease Inhibitors and Albumin), Application (Immunology, Neurology, Critical Care, Hematology and Pulmonary), End users (Hospitals, Clinical Research Laboratories and Academic Institutions) - Analysis & Forecast 2019-2030

Report ID : 166  |  Published Date : Jan 2020  |  Pages : 160  |  Region : Global  |  Report Code : PH-10





Plasma Fractionation Market Overview and Introduction

Plasma fractionation is a general process of separating various components of blood plasma. Plasma fractionation was developed by Cohn and is carried out at low temperatures by the addition of ethanol in 8% to 40% V/V at the end, for albumin separation. Nowadays, plasma fractionation can also be carried out with the combination of chromatographic techniques to achieve higher quality and yield. Plasma fractionation is used for the treatment of immunological disorders, protein deficiency and several other medical applications.

The growth of the plasma fractionation market can be attributed to a wide range of therapeutic applications of this technique, increasing prevalence of auto-immune disorders, increasing number of hemophilic patients, rising prevalence of respiratory disorders, and increasing generic population among others. Proteins present in plasma have several therapeutic applications, similarly, plasma-derived proteins can also be used as a biomarker in the diagnosis of diseases. However, high costs, stringent government regulations, and limited reimbursement are anticipated to restrain the growth of the market.

The plasma fractionation market is segmented by product type, application, end-users, and region.

Plasma Fractionation Market By Product

Based on product, the plasma fractionation market is segmented into coagulation factor concentrates, immunoglobulin, protease inhibitors, albumin, and other plasma-derived products. Coagulation factor concentrates can be further segmented into factor VII, factor IX, factor VII, prothrombin coagulation concentrates, Von Willebrand factors, and fibrinogen concentrates. Whereas, immunoglobulin can be further segmented into subcutaneous immunoglobulin and intravenous immunoglobulin. Based on product, the immunoglobulin market is expected to account for the largest market share during the forecast period. 

Plasma Fractionation Market By Application

Based on application, the plasma fractionation market is segmented into immunology, neurology, critical care, hematology, and pulmonary. Neurology and hematology are expected to account for the largest market share during the forecast period owing to rising incidences of neurological disorders and the increasing number of anemic patients globally. 

Plasma Fractionation Market By End User

Based on end user, the plasma fractionation market is segmented into hospitals, clinical research laboratories, and academic institutions. Hospitals is anticipated dominate the plasma fractionation market in 2019.

Plasma Fractionation Market by Region

The plasma fractionation market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America accounted for the largest market share in 2019, owing to the rising number of hemophilic patients, increasing use of immunoglobulin for therapeutics application, rising prevalence of respiratory diseases, and increasing generic population. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period owing to the increasing aging population, and increasing prevalence of hemophilic patients in this region.

Plasma Fractionation Market Prominent Players

Some prominent players in the plasma fractionation market include Octapharma AG, CSL Ltd., China Biologics Products Holdings, Inc., Baxter International Inc., Kendrion, Biotest, Shanghai RAAS blood products Co., Ltd., GRIFOLs, Takeda Biopharmaceuticals, and Bio Products Laboratory, among others.

Table of Contents

  1. INTRODUCTION
    1. Market Definition
    2. Market Classification
    3. Geographic Scope
    4. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecast Years – 2019 to 2030
    5. Currency Used
  2. RESEARCH METHODOLOGY
    1. Research Framework
    2. Data Collection Technique
    3. Data Sources
      1.  Secondary Sources
      2.  Primary Sources
    4. Market Estimation Methodology
      1.  Bottom Up Approach
      2.  Top Down Approach
    5. Data Validation and Triangulation
      1.  Market Forecast Model
      2.  Limitations/Assumptions of the Study
  3. ABSTRACT OF THE STUDY
  4. MARKET DYNAMICS ASSESSMENT
    1. Overview
    2. Drivers
    3. Barriers/Challenges
    4. Opportunities
  5. UNIQUE SELLING PROPOSITIONS (USPs)
    1. Research Landscape Assessment
  6.  PLASMA FRACTIONATION MARKET - ANALYSIS & FORECAST, BY PRODUCT
    1. Coagulation Factor Concentrates
      1. Factor VII
      2. Factor IX
      3. Factor XII
      4. Prothrombin Coagulation Concentrates
      5. Von Willebrand Factor
      6.  Fibrinogen Concentrates
    2. Immunoglobulin
      1. Subcutaneous Immunoglobulin
      2. Intravenous Immunoglobulin
    3. Protease Inhibitors
    4. Albumin
    5. Other Plasma Products
  7.  PLASMA FRACTIONATION MARKET - ANALYSIS & FORECAST, BY APPLICIATION 
    1. Immunology
    2. Neurology
    3. Critical Care
    4. Hematology
    5. Pulmonology
    6. Other Applications
  8.  PLASMA FRACTIONATION MARKET - ANALYSIS & FORECAST, BY END USERS 
    1. Hospitals
    2. Clinical Research Laboratories
    3. Academic Institutions
  9.  PLASMA FRACTIONATION MARKET - ANALYSIS & FORECAST, BY REGION
    1.   North America Plasma Fractionation Market
      1.  North America Plasma Fractionation  Market, By Country
        1.  US
        2.  Canada
      2. North America Plasma Fractionation Market Analysis & Forecast, By Product
      3. North America Plasma Fractionation Market Analysis & Forecast, By Application
      4. North America Plasma Fractionation Market Analysis & Forecast, By End User
    2. Europe Plasma Fractionation Market
      1. Europe Plasma Fractionation  Market, By Country/Region
        1. Germany
        2. UK
        3. France
        4. Rest of Europe (ROE)
      2. Europe Plasma Fractionation Market Analysis & Forecast, By Product
      3. Europe Plasma Fractionation Market Analysis & Forecast, By Application
      4. Europe Plasma Fractionation Market Analysis & Forecast, By End User
    3. Asia Pacific Plasma Fractionation Market
      1. Asia Pacific Plasma Fractionation  Market, By Country/Region
        1. China
        2. Japan
        3. India
        4. Rest of Asia Pacific (RoAPAC)
      2. Asia Pacific Plasma Fractionation Market Analysis & Forecast, By Product
      3. Asia Pacific Plasma Fractionation Market Analysis & Forecast, By Application
      4. Asia Pacific Plasma Fractionation Market Analysis & Forecast, By End User
    4.   Rest of the World (ROW) Plasma Fractionation Market
      1. Rest of the World Plasma Fractionation  Market, By Country/ Region
        1.  Latin America
        2.  Middle East & Africa
      2. Rest of the World Plasma Fractionation Market Analysis & Forecast, By Product
      3. Rest of the World Plasma Fractionation Market Analysis & Forecast, By Application
      4. Rest of the World Plasma Fractionation Market Analysis & Forecast, By End User
  10. COMPETITIVE LANDSCAPE
    1. Key Players & Their Competitive Positioning (2018)
    2. Key Strategies Assessment
      1. New Product Launches
      2. Merger & Acquisitions
      3. Agreements, Collaborations, & Partnerships
      4. Expansions
      5. Other Strategies
  11. COMPANY PROFILES (Business Overview, Products Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*
    1. Octapharma
    2. CSL Ltd.
    3. China Biologics Products Holdings, Inc.
    4. Baxter
    5. Kendrion
    6. Biotest AG
    7. Shanghai RAAS
    8. GRIFOLs, SA.
    9. Takeda Biopharmaceuticals Company Limited
    10. Bio Products Laboratory Ltd.            

*Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain